In summary, cancer cells with activated and mutant EGFR may inhibit NK cell infiltration and cytotoxicity by expressing certain cytokines, and reduce the expression of ligands for NK cell activation receptors in cancer cells, contributing to tumor‐mediated immune escape. The gene discussed is EGFR; the disease is neoplasm.